Adaptive Biotechnologies Corporation
ADPT
$15.42
-$0.70-4.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.04% | 102.38% | 36.33% | 25.24% | 3.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.04% | 102.38% | 36.33% | 25.24% | 3.66% |
| Cost of Revenue | 12.86% | 2.44% | -5.68% | -14.73% | -227.61% |
| Gross Profit | 14.92% | 830.37% | 1,231.49% | 275.32% | 4,334.87% |
| SG&A Expenses | 11.12% | 9.57% | 8.24% | -3.51% | -7.04% |
| Depreciation & Amortization | 0.23% | 0.00% | -0.24% | -0.95% | -0.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.88% | 5.84% | 0.73% | -9.48% | -11.08% |
| Operating Income | 62.25% | 131.53% | 37.59% | 39.29% | 25.86% |
| Income Before Tax | 59.73% | 129.74% | 44.66% | 37.24% | 51.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.73% | 129.74% | 44.66% | 37.24% | 51.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -96.15% | -180.77% | -184.62% | -3.85% |
| Net Income | 59.70% | 129.77% | 44.58% | 37.16% | 51.48% |
| EBIT | 62.25% | 131.53% | 37.59% | 39.29% | 25.86% |
| EBITDA | 70.81% | 152.41% | 41.52% | 42.88% | 26.98% |
| EPS Basic | 61.11% | 128.79% | 46.30% | 38.60% | 52.40% |
| Normalized Basic EPS | 61.94% | 128.79% | 36.34% | 39.93% | 26.57% |
| EPS Diluted | 59.58% | 127.27% | 46.30% | 38.60% | 52.40% |
| Normalized Diluted EPS | 61.94% | 126.95% | 36.34% | 39.93% | 26.57% |
| Average Basic Shares Outstanding | 3.69% | 3.33% | 3.17% | 2.34% | 1.92% |
| Average Diluted Shares Outstanding | 3.69% | 10.61% | 3.17% | 2.34% | 1.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |